Indication
Plasmacytoma
7 clinical trials
8 products
7 drugs
Clinical trial
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell TherapyStatus: Recruiting, Estimated PCD: 2027-07-11
Product
CAR-T cellsClinical trial
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell LeukemiaStatus: Completed, Estimated PCD: 2020-10-30
Product
DexamethasoneProduct
Ixazomib CitrateDrug
PomalidomideClinical trial
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory MyelomaStatus: Recruiting, Estimated PCD: 2024-12-31
Drug
CarfilzomibDrug
dexamethasoneProduct
LenalidomideDrug
NavtemadlinClinical trial
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Product
IxazomibClinical trial
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)Status: Active (not recruiting), Estimated PCD: 2024-11-19
Product
CC-486Clinical trial
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic CancerStatus: Completed, Estimated PCD: 2018-05-01
Product
Sodium SeleniteClinical trial
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed MyelomaStatus: Completed, Estimated PCD: 2024-06-03
Product
BusulfanDrug
GemcitabineDrug
MelphalanDrug
panobinostat